Program Description

This program provides healthcare professionals with the latest advancements in the systemic management of advanced or metastatic RCC. Participants will learn to apply risk stratification and patient-specific factors to individualize treatment decisions. The curriculum includes the integration of recent clinical trial data, expert opinions, and guidelines to optimize first-line and subsequent therapies. Additionally, the program covers strategies for therapy sequencing and managing adverse events associated with IO-based combination therapies, particularly in government and military healthcare settings. By equipping clinicians with essential knowledge and tools, this education supports improved patient outcomes through evidence-based treatment decisions.

Intended Audience

This activity is designed to meet the educational needs of urologists as well as medical oncologists, surgical oncologists, urologists and other healthcare professionals involved in the treatment of patients with RCC.

Commercial Supporters

This activity is supported by an educational grant from Merck Sharp & Dohme.

Educational Objectives

Upon completion of the educational activity, participants should be able to:

• Describe the role of risk stratification and other patient and disease-specific factors used to individualize therapies for patients with advanced or metastatic RCC.
• Integrate the most recent clinical trial data, expert opinions, and guideline recommendations to select the optimal first-line therapy for individual patients with advanced or metastatic RCC.
• Analyze the available strategies for the second- and later-line treatment of advanced or metastatic RCC, including considerations for therapy sequencing.
• Implement strategies to monitor and mitigate adverse events associated with IO-based combination therapies in government and military healthcare settings.

Accredited Provider

This activity is provided by Medical Education Resources (MER) and PleXus Communications

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Medical Education Resources (MER) and PleXus Communications. MER is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA PRA Category 1 CreditTM

Medical Education Resources designates this online activity for a maximum of 1.00 AMA PRA Category 1 CreditTM. Physicians should claim only credit commensurate with the extent of their participation in the activity.

ANCC Contact Hour

Medical Education Resources designates this online activity for a maximum of 1.00 ANCC contact hour. 

Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299, for 1.00 contact hours.

CE for Pharmacists

Medical Education Resources (MER) designates this continuing education activity for 1.00 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education. 

Universal Program Number – JA0003680-9999-25-066-H01-P

This activity is certified as Knowledge based CPE. 

The record of your participation in this CE activity will be uploaded to the CPE Monitor under your NABP e-profile within 60 days.

You may print an individual statement of credit for this activity from your NABP e-profile.

Disclosure of All Financial Relationships

Medical Education Resources ensures balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, MER identifies all financial relationships with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Reported relevant financial relationships are mitigated by MER to ensure that all scientific research referred to, reported, or used in an accredited continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing learners with high-quality accredited continuing education activities that promote improvements or quality in health care and not the business interest of an ineligible company.

Accredited Provider Disclosures

The provider of this activity has nothing to disclose.

Planners’ and Managers’ Disclosures

The remaining planners and managers of this activity have nothing to disclose.

Disclosure of Unlabeled Use

In accordance with requirements of the FDA, the audience is advised that information presented in some continuing education activities may contain references to unlabeled or unapproved uses of drugs or devices. Please refer to the FDA-approved package insert for each drug/device for full prescribing/utilization information.

Disclaimer

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources, PleXus Communications, and Merck Sharp & Dohme. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.